Evidence check: CYP2C19 in the context of Allergie

CYP2C19 is a gene encoding a cytochrome P450 enzyme primarily involved in drug metabolism, such as proton pump inhibitors, clopidogrel, and some antidepressants. In the context of allergies, the evidence is weak. Some studies suggest that CYP2C19 variants may influence the metabolism of certain antihistamines or corticosteroids, potentially affecting treatment response. However, these effects are modest and not clinically established. Consumer DNA tests that include CYP2C19 are not validated for allergy risk or management. Allergy diagnosis relies on IgE testing, skin prick tests, and clinical history, not genetic markers. Therefore, the evidence for CYP2C19 in allergy is mechanistic and speculative at best. Consulting an allergist remains the standard of care.